01—Abstract
Summary
Summary of the 10-K filed February 22, 2010. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2009 10-K filing highlights a year of revenue growth driven by key products like Alimta, Cymbalta, Humalog, and Zyprexa, along with the inclusion of Erbitux following the ImClone acquisition.
The company also faced significant legal and regulatory challenges, notably related to Zyprexa's marketing practices and ongoing patent litigation for several major products, which resulted in substantial charges and ongoing legal defense costs. Looking ahead, Lilly emphasized its commitment to research and development, with over 60 drug candidates in human testing across various therapeutic areas.
However, the company also acknowledged the critical challenge posed by upcoming patent expirations for several of its blockbuster drugs within the next few years, which will likely impact future revenues. Management is focused on cost-reduction initiatives and strategic business development to mitigate these patent cliff impacts and maintain long-term growth.
02—Key points
Key Highlights
- Total revenue grew by 7% to $21.84 billion in 2009, primarily driven by Alimta, Cymbalta, Humalog, and Zyprexa, along with the acquisition of ImClone Systems.
- The company faced significant legal settlements and charges related to past marketing and promotional practices for Zyprexa, totaling $1.48 billion in 2008 and additional charges in 2009.
- Eli Lilly is heavily invested in R&D, with over 60 drug candidates in human testing across key therapeutic areas like CNS, endocrinology, oncology, and cardiovascular diseases.
- Several major products are nearing patent expiration, with Zyprexa, Cymbalta, Humalog, and Alimta among those set to lose significant patent protection in the coming years, posing a future revenue risk.
- The company is implementing cost-reduction measures, aiming to reduce its expected cost structure by $1 billion by the end of 2011.
- Cash flow from operations was robust at $4.34 billion in 2009, supporting debt repayment and dividend payments.
- Product liability claims, particularly for Zyprexa, continue to be a significant area of litigation and potential financial exposure for the company.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2009filed February 22, 2010Financial Statements
FY2009 against FY2008
| Line item | FY2009FY2008 | Change |
|---|---|---|
| Revenue | $21.84B$20.37B | +7.2% |
| Cost of Revenue | $4.25B$4.38B | −3.0% |
| Gross Profit | $17.59B$16.00B | +10.0% |
| R&D Expenses | $4.33B$3.84B | +12.6% |
| SG&A Expenses | $6.89B$6.63B | +4.0% |
| Interest Expense | $261.30M-$228.30M | +214.5% |
| Net Income | $4.33B-$2.07B | +308.9% |
| EPS (Basic) | $3.94$-1.89 | +308.5% |
| EPS (Diluted) | $3.94$-1.89 | +308.5% |
| Shares Outstanding (Basic) | 1.10B1.09B | +0.4% |
| Shares Outstanding (Diluted) | 1.10B1.09B | +0.4% |
05—Questions
Frequently Asked Questions
What were the main drivers of revenue growth in 2009?
Revenue growth in 2009 was primarily driven by the collective growth of Alimta, Cymbalta, Humalog, and Zyprexa. The acquisition of ImClone Systems in late 2008 also contributed to revenue through Erbitux sales.
What are the most significant risks facing Eli Lilly based on this filing?
The most significant risks include the upcoming patent expirations for key revenue-generating products like Zyprexa, Cymbalta, and Humalog, which will lead to increased generic competition and potential sales declines. Additionally, ongoing litigation and government investigations, particularly those related to Zyprexa's marketing practices, pose significant financial and reputational risks.
How is Eli Lilly managing the impact of upcoming patent expirations?
The company is focusing on its robust R&D pipeline, with over 60 drug candidates in development, and strategic business development activities to bring new innovative medicines to market. It is also implementing cost-reduction initiatives to mitigate the financial impact of losing market exclusivity on key products.
What is the company's stance on the Zyprexa litigation and related charges?
Eli Lilly has resolved investigations and litigation related to Zyprexa's marketing and promotional practices with various state and federal authorities, incurring significant charges. While many claims have been settled, the company continues to defend itself in remaining product liability lawsuits, acknowledging the potential for adverse impacts on future results.
06—Continue